🍽️ trapidil,(prescription)

AI Engines For more Details: Perplexity  Kagi Labs  You 

  1. Coronary Artery Disease (CAD):

    • Trapidil is indicated for the treatment of coronary artery disease, a condition characterized by the narrowing or blockage of the coronary arteries that supply blood to the heart muscle. By dilating blood vessels, trapidil helps improve blood flow to the heart, thereby relieving angina symptoms and reducing the risk of myocardial ischemia.

  2. Angina Pectoris:

    • Trapidil is effective in the management of angina pectoris, a type of chest pain or discomfort caused by reduced blood flow to the heart muscle due to coronary artery disease. By dilating coronary arteries and improving blood flow, trapidil helps alleviate angina symptoms such as chest pain, pressure, or tightness.

  3. Vasospastic Angina (Prinzmetal's Angina):

    • Trapidil may be used to treat vasospastic angina, also known as Prinzmetal's angina or variant angina. This condition involves sudden spasms or narrowing of the coronary arteries, leading to episodes of chest pain or discomfort. Trapidil's vasodilatory effects can help prevent or relieve coronary artery spasm, thereby reducing angina symptoms.

  4. Peripheral Arterial Disease (PAD):

    • Trapidil may also be prescribed for the management of peripheral arterial disease, a condition characterized by narrowed arteries in the limbs (usually the legs) due to atherosclerosis. By dilating peripheral arteries, trapidil can improve blood flow to the limbs, alleviate symptoms such as leg pain or cramping (intermittent claudication), and promote walking distance.

  5. Vascular Disorders:

    • Trapidil's vasodilatory properties make it potentially useful in the treatment of various vascular disorders characterized by abnormal constriction or narrowing of blood vessels. These may include conditions such as Raynaud's phenomenon, in which small arteries spasm in response to cold or stress, leading to reduced blood flow to the fingers and toes.

  6. Platelet Aggregation Inhibition:

    • Trapidil may possess antiplatelet effects, which could help prevent blood clot formation (platelet aggregation) and reduce the risk of thrombotic events such as heart attack or stroke in individuals with cardiovascular disease.

  7. Side Effects:

    • Common side effects of trapidil may include headache, dizziness, flushing, nausea, vomiting, and gastrointestinal disturbances. Less common but potentially serious side effects may include hypotension (low blood pressure), allergic reactions, and abnormal liver function tests.
;

Check for interactions on Supp.AI   |   📚 PubMed Citations

⚗️ Compensation for antibiotic usage

Data Contradictions — Limits of Certainity

Impacted of trapidil,(prescription) On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Bifidobacterium longum Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by trapidil,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

🧙?

Taxonomy Rank Effect Citations Notation
Dorea genus Decreases 👪 Source Study
Ruminococcus genus Decreases 👪 Source Study
Agathobacter genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Lachnospira genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Dorea formicigenerans species Decreases 📓 Source Study
Mediterraneibacter gnavus species Decreases 📓 Source Study
Bifidobacterium longum species Decreases 📓 Source Study
Bacteroides thetaiotaomicron species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suis subspecies Decreases 👶 Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study

Impact of trapidil,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.1 0.1
Acne 0.3 -0.3
ADHD 1.5 0.3 4
Age-Related Macular Degeneration and Glaucoma 0.6 0.6
Allergic Rhinitis (Hay Fever) 1.5 0.6 1.5
Allergies 1.6 1.2 0.33
Allergy to milk products 0.6 0.6 0
Alopecia (Hair Loss) 0.6 0.6
Alzheimer's disease 1.9 2.1 -0.11
Amyotrophic lateral sclerosis (ALS) Motor Neuron 1 0.3 2.33
Ankylosing spondylitis 2 1.3 0.54
Anorexia Nervosa 0.9 1.5 -0.67
Antiphospholipid syndrome (APS) 0.4 0.4
Asthma 2.5 1.2 1.08
Atherosclerosis 1.2 1.2
Atrial fibrillation 2.6 0.6 3.33
Autism 2.7 2.9 -0.07
Autoimmune Disease 0.6 0.3 1
Barrett esophagus cancer 0.6 0.3 1
benign prostatic hyperplasia 0.3 -0.3
Biofilm 0.8 0.8
Bipolar Disorder 0.9 0.9 0
Brain Trauma 0.6 0.9 -0.5
Breast Cancer 0.1 0.1
Cancer (General) 0.6 0.4 0.5
Carcinoma 2.4 1.5 0.6
Celiac Disease 0.9 2.1 -1.33
Cerebral Palsy 1.2 0.6 1
Chronic Fatigue Syndrome 2.2 2.2 0
Chronic Kidney Disease 1.5 0.3 4
Chronic Lyme 0.3 -0.3
Chronic Obstructive Pulmonary Disease (COPD) 1 1.2 -0.2
Chronic Urticaria (Hives) 0.6 0.6
Coagulation / Micro clot triggering bacteria 0.3 0.6 -1
Cognitive Function 1.7 0.6 1.83
Colorectal Cancer 2 0.9 1.22
Constipation 0.9 0.9
Coronary artery disease 1 0.6 0.67
COVID-19 2.7 3.4 -0.26
Crohn's Disease 2.8 2.3 0.22
Cushing's Syndrome (hypercortisolism) 0.3 -0.3
cystic fibrosis 0.6 -0.6
deep vein thrombosis 0.1 0.9 -8
Denture Wearers Oral Shifts 0.6 0.6
Depression 2.7 2.7 0
Dermatomyositis 0.3 0.3 0
Eczema 1 0.7 0.43
Endometriosis 1.4 0.9 0.56
Eosinophilic Esophagitis 0.3 0.6 -1
Epilepsy 1.2 0.6 1
erectile dysfunction 0.6 0.3 1
Fibromyalgia 1.6 0.6 1.67
Functional constipation / chronic idiopathic constipation 1.5 0.9 0.67
gallstone disease (gsd) 1.3 0.6 1.17
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.7 0.6 0.17
Generalized anxiety disorder 1.2 0.9 0.33
Glioblastoma 0.3 -0.3
Gout 0.9 0.9
Graves' disease 1.2 2 -0.67
Gulf War Syndrome 0.3 0.4 -0.33
Halitosis 1.3 0.3 3.33
Hashimoto's thyroiditis 2 0.9 1.22
Heart Failure 1.3 0.7 0.86
hemorrhagic stroke 0.9 0.9
Hidradenitis Suppurativa 1.2 0.3 3
High Histamine/low DAO 0.6 -0.6
hyperglycemia 0.2 0.6 -2
Hyperlipidemia (High Blood Fats) 0.3 0.3
hypertension (High Blood Pressure 2 1.5 0.33
Hypothyroidism 0.6 -0.6
Hypoxia 1.2 0.3 3
IgA nephropathy (IgAN) 1.5 0.9 0.67
Inflammatory Bowel Disease 2.5 2.5 0
Insomnia 1.6 1.7 -0.06
Intelligence 0.3 0.3
Intracranial aneurysms 0.9 0.9
Irritable Bowel Syndrome 2.3 1.7 0.35
ischemic stroke 1.5 0.6 1.5
Liver Cirrhosis 3.1 2.3 0.35
Long COVID 2.9 2.7 0.07
Low bone mineral density 0.3 -0.3
Lung Cancer 0.9 -0.9
Mast Cell Issues / mastitis 0.4 0.6 -0.5
ME/CFS with IBS 0.3 0.7 -1.33
ME/CFS without IBS 0.7 1.2 -0.71
membranous nephropathy 0.3 0.3
Menopause 0.4 0.4
Metabolic Syndrome 2.4 2.8 -0.17
Mood Disorders 2.2 2.4 -0.09
multiple chemical sensitivity [MCS] 0.7 0.7
Multiple Sclerosis 2.2 1.5 0.47
Multiple system atrophy (MSA) 0.6 -0.6
myasthenia gravis 0.3 0.3
neuropathic pain 0.3 0.9 -2
Neuropathy (all types) 0.6 0.6
neuropsychiatric disorders (PANDAS, PANS) 0.3 0.3
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 2.4 1.3 0.85
NonCeliac Gluten Sensitivity 0.9 0.6 0.5
Obesity 2.9 3.5 -0.21
obsessive-compulsive disorder 1.2 1.8 -0.5
Osteoarthritis 1.1 1.2 -0.09
Osteoporosis 1.2 1.2 0
pancreatic cancer 0.4 0.3 0.33
Parkinson's Disease 1.3 3.9 -2
Polycystic ovary syndrome 1.6 1.2 0.33
Postural orthostatic tachycardia syndrome 0.3 -0.3
Premenstrual dysphoric disorder 0.3 0.3
primary biliary cholangitis 1.2 0.6 1
Primary sclerosing cholangitis 1.2 0.4 2
Psoriasis 1.3 0.3 3.33
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2.7 1.8 0.5
Rosacea 0.6 0.6
Schizophrenia 2.4 1.5 0.6
scoliosis 0.5 -0.5
Sjögren syndrome 0.6 1.4 -1.33
Sleep Apnea 1.7 0.9 0.89
Slow gastric motility / Gastroparesis 0.9 0.3 2
Small Intestinal Bacterial Overgrowth (SIBO) 1.2 0.1 11
Stress / posttraumatic stress disorder 1.4 0.6 1.33
Systemic Lupus Erythematosus 1.5 1.4 0.07
Tic Disorder 0.6 0.9 -0.5
Tourette syndrome 0.9 0.3 2
Type 1 Diabetes 1.2 1.9 -0.58
Type 2 Diabetes 2.7 2.7 0
Ulcerative colitis 2.6 0.9 1.89
Unhealthy Ageing 2.2 0.3 6.33
Vitiligo 1.5 0.3 4

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [216.73.216 ]